作者: Carmine Pinto , Carlo Antonio Barone , Giampiero Girolomoni , Elvio Grazioso Russi , Marco Carlo Merlano
DOI: 10.1634/THEONCOLOGIST.2010-0298
关键词:
摘要: Background. Cetuximab was demonstrated by clinical trials to improve response rate and survival of patients with metastatic nonresectable colorectal cancer or carcinoma the head neck. Appropriate management skin toxicity associated epidermal growth factor receptor inhibitor (EGFR-i) therapy is necessary allow adequate drug administration quality life outcomes.